UGT2B17 and prostate adenocarcinoma: In the present study, we found two mutations in UGT2B15 [c.249A > T (Lys83Asp), c.436T > A (Phe146Ile)] and one mutation in UGT2B17 [c.1193C > G (Ala398Gly)] in PRAD tumors (Table S3).